Yifan Pharmaceuticals announced that its wholly-owned subsidiary Yifan Pharmaceuticals (Shanghai) Co., Ltd. recently received the "Notice of Approval for Drug Clinical Trial" approved and issued by the National Medical Products Administration. The drug name is human growth hormone injection, the English name is Human Somatropin Injection, the dosage form is injection, and the registration classification is Class 3.3 of therapeutic biological products. According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, it is agreed to conduct clinical trials in accordance with the requirements of biosimilars. Human growth hormone injection is a biosimilar developed by the company to Novo Nordisk's recombinant human growth hormone injection (trade name: Noze), which has the same amino acid sequence as natural human growth hormone and is currently the mainstream treatment for growth hormone deficiency.